For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 57,647 | |||
| Research and development - related party | 600 | |||
| General and administrative | 12,410 | |||
| Total operating expenses | 70,657 | |||
| Loss from operations | -70,657 | |||
| Interest income | 2,715 | |||
| Other expense, net | -396 | |||
| Total other income, net | 2,319 | |||
| Net loss before taxes | -68,338 | |||
| Income tax expense | 1,037 | |||
| Net loss | -69,375 | |||
| Basic EPS | -4.71 | |||
| Diluted EPS | -4.71 | |||
Forte Biosciences, Inc. (FBRX)
Forte Biosciences, Inc. (FBRX)